Key clinical point: Routine use of Oncotype DX testing to personalize breast cancer treatment will likely slightly reduce health care costs.
Major finding: The projected total first-year costs of care were $2.816 billion before and $2.766 billion after the TAILORx trial, for a net savings of $49 million (1.8% decrease).
Study details: A population-based cohort study using Surveillance, Epidemiology and End Results data to estimate costs for 96,529 patients treated in 2010-2015 (before TAILORx) and 67,563 patients treated in 2018 (after TAILORx).
Disclosures: The investigators reported that they had no relevant conflicts of interest. The study was supported by the National Cancer Institute and its Coordinating Center For Clinical Trials; a Lombardi Comprehensive Cancer Center American Cancer Society Young Investigator Award; and the Cancer Prevention Research Fellowship, sponsored by the American Society of Preventive Oncology and Breast Cancer Research Foundation.
Mariotto A et al. J Natl Cancer Inst. 2019 Apr 24. doi: 10.1093/jnci/djz068.